Positive Quality Intervention: Daratumumab (Darzalex®) for Multiple Myeloma

Description: Daratumumab is an anti-CD38 monoclonal antibody (mAb) FDA approved for use in a range of multiple myeloma patients including first line, transplant-ineligible, and refractory.¹ This PQI will provide guidance for optimal administration and management of both daratumumab infusions and subcutaneous formulation.

Background: Daratumumab is administered as a single agent or in combination with other multiple myeloma treatment options including proteasome inhibitors and immunomodulating agents.¹ One of the most common adverse reactions of daratumumab is infusion-related reactions (IRRs) of any grade. The occurrence rate is observed at 37% with the first (16 mg/kg, week 1) infusion¹ and one study observed the occurrence rate rising to 58% in patients who did not receive montelukast prior to their first infusion.³ The median time to onset of an IRR is 1.5 hours (range 0-73 hours).¹ IRRs often present with symptoms similar to allergic rhinitis such as cough, wheezing, and rhinorrhea due to CD38 expression on airway smooth muscle cells.⁴ An option to manage IRRs is to split the first dose over 2 days, with daratumumab administered at a dose of 8mg/kg on days 1 and 2.¹ DARZALEX FASPRO® utilizes flat dosing at (1,800 mg daratumumab and 30,000 units hyaluronidase) administered subcutaneously into the abdomen over approximately 3 to 5 minutes.²

PQI Process: Prior to the first infusion:
- Verify concomitant medications to be given with daratumumab and determine the dosing frequency
  - Review Infusion rates, duration, and dilution volumes (see Supplemental Information)¹,⁴
- Ensure orders are placed for premedications - administer 1-3 hours before start of infusion¹
  - Corticosteroid-intermediate or long acting such as methylprednisolone 100mg IV
  - Acetaminophen 650 -1000 mg PO
  - Diphenhydramine 25-50 mg IV or PO
- Consider adding an H2RA and LRA for the first 2-3 infusions then as needed³
  - Montelukast (Singular®) 10 mg PO x 1
  - Famotidine 20 mg IV
- Determine duration and dose of post-infusion corticosteroids to reduce the risk of delayed infusion reactions
- Consider prescribing short and long-acting bronchodilators and inhaled corticosteroids for patients with chronic obstructive pulmonary disease
  - Discontinue after 4 infusions if the patient does not experience any major infusion reactions
- To prevent medication errors, it is important to check the vial labels to ensure that the drug being prepared and administered is correct between either DARZALEX FASPRO® for subcutaneous injection or DARZALEX® for intravenous infusion
- Determine if day 1 will be administered as a single dose or a split dose
  - Split doses can be considered for clinics with shorter hours of operation and may result in cost savings if full infusion is not able to be completed due to time constraints or reaction
- Patients experiencing grades 1-3 infusion reactions can be rechallenged
  - Permanently discontinue for the 3rd occurrence of a Grade 3 or any Grade 4 infusion reaction¹
- Verify with immunohematology and laboratories/transfusion medicine departments that patient will be receiving CD38 mAbs and provide patient with a wallet card that specifies the blood profile (ABO, Rh, and IST) * This should be determined before the first infusion of daratumumab
- Initiate antiviral prophylaxis to prevent herpes zoster reactivation within 1 week of starting and continue

IMPORTANT NOTICE: NCODA has developed this Positive Quality Intervention platform. This platform is intended as an educational aid, does not provide individual medical advice, and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication. The materials contained in this platform do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA. NCODA does not ensure the accuracy of the information presented and assumes no liability relating to its accuracy. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional. It is the individual’s sole responsibility to seek guidance from a qualified healthcare professional. Updated 1.12.23
for 3 months following completion of treatment

- Check hepatitis B status and advise that daratumumab administration could reactivate the virus
- Infusion set fitted with a flow regulator and an in-line sterile, non-pyrogenic, low protein-binding polyethersulfone (PES) filter (0.22 or 0.2 micrometer) is required, do not infuse in the same line as other medications
- Monitor patient for infusion reactions and manage infusion reactions per institutional standards
  - Infusion-related reactions occurred in 37% of patients with the Week 1 (16 mg/kg) infusion, 2% with the Week 2 infusion, and cumulatively 6% with subsequent infusions. Less than 1% of patients had a Grade 3/4 infusion-related reaction at Week 2 or subsequent infusions⁴

Prior to the second infusion (week 2)

- Determine if patient experienced an infusion reaction during the previous infusion
  - If no reaction, prepare daratumumab in the week 2 volume of 500 mL and administer via the rate titrations listed below for week 2
  - If an infusion reaction occurred during the first infusion, use the dilution volume of 1,000 mL
- Check CBC for neutropenia and thrombocytopenia regularly during treatment

Prior to the third and subsequent infusions (week 3 and beyond)

- Determine if patient experienced an infusion reaction during the previous infusion and repeat prior infusion if reaction occurred
- If no infusion reaction occurs during the second week of infusion, rapid administration can be considered
  - Monitor vital signs prior to infusion, every 15 minutes for the first hour, and at the end of the infusion
  - Observe patient for signs and symptoms of an infusion reaction for 30 minutes following rapid infusion

Patient-Centered Activities:

- Counsel patient on disease state, treatment regimen, adverse reactions, and verify understanding
- Initiate antiviral prophylaxis to prevent herpes zoster reactivation within 1 week of starting and continue for 3 months following completion of treatment
- Check hepatitis B status and advise that daratumumab administration could cause reactivation
- Provide patient with treatment calendar outlining planned treatment schedule
- Provide patient with wallet card detailing blood profile
  - This card should be carried throughout treatment and at least 6 months after treatment ends

References:

1. Darzalex® (daratumumab) [prescribing information].
2. Darzalex Faspro® (daratumumab and hyaluronidase-fihj) [prescribing information].
### Supplemental Information:
**Infusion rates, duration, and dilution volumes for daratumumab administrations**

<table>
<thead>
<tr>
<th>Dilution Volume</th>
<th>Initial Rate (1st hour)</th>
<th>Rate Increment (absence of reaction)</th>
<th>Maximum rate</th>
<th>Average Infusion Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Week 1</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Option 1: Single Dose (16 mg/kg)</td>
<td>1,000 mL</td>
<td>50 mL/hour</td>
<td>50 mL/hour every hour</td>
<td>200 mL/hour</td>
</tr>
<tr>
<td>Option 2 Split Dose: Week 1 Day 1 (8 mg/kg)</td>
<td>500 mL</td>
<td>50 mL/hour</td>
<td>50 mL/hour every hour</td>
<td>200 mL/hour</td>
</tr>
<tr>
<td>Option 2 Split Dose: Week 1 Day 2 (8 mg/kg)</td>
<td>500 mL</td>
<td>50 mL/hour</td>
<td>50 mL/hour every hour</td>
<td>200 mL/hour</td>
</tr>
<tr>
<td><strong>Week 2 (16mg/kg)</strong></td>
<td>500 mL</td>
<td>50 mL/hour</td>
<td>50 mL/hour every hour</td>
<td>200 mL/hour</td>
</tr>
<tr>
<td><strong>Week 3 &amp; Beyond (16mg/kg)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Option 1: Standard Infusion</td>
<td>500 mL</td>
<td>100 mL/hour</td>
<td>50 mL/hour every hour</td>
<td>200 mL/hour</td>
</tr>
<tr>
<td>Option 2: 90 Minute Infusion</td>
<td>500 mL</td>
<td>200 mL/hour for 30 minutes (20% of dose)</td>
<td>450 mL/hour over 60 minutes (80% of dose)</td>
<td>90 minutes</td>
</tr>
</tbody>
</table>